Oncolytics Enters into Sponsorship Agreement with NCIC CTG
News May 04, 2012
Oncolytics Biotech Inc. has announced that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN® in patients with advanced or metastatic colorectal cancer.
"We are pleased to be conducting a second randomized study with the NCIC CTG," said Dr. Brad Thompson, President and CEO of Oncolytics.
Dr. Thompson continued, "This study will build on both our early preclinical and clinical colorectal cancer work, as well as preclinical research combining REOLYSIN with Avastin®. As a Company, we intend to continue expanding our clinical program to include randomized studies of frequently diagnosed cancers."
The study will be an open-label, randomized, non-blinded, Phase II clinical study of REOLYSIN given in combination with FOLFOX-6 plus bevacizumab (Avastin) versus FOLFOX-6 plus bevacizumab alone.
Approximately 50 response evaluable patients will be enrolled in each arm, after a six to nine patient safety run in.
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Glythera Appoints Chief Scientific Officer and Strengthens SABNews
Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates. Dr Jon Roffey appointed to Scientific Advisory Board.READ MORE